Please login to the form below

Not currently logged in
Email:
Password:

Novartis Oncology

This page shows the latest Novartis Oncology news and features for those working in and with pharma, biotech and healthcare.

Novartis gets speedy reviews for new Kymriah filings

Novartis gets speedy reviews for new Kymriah filings

Novartis gets speedy reviews for new Kymriah filings. US and EU regulatory agencies will review the drug for DLBCL patients. ... Approval would lead to a sizeable expansion in the eligible patient population for Kymriah, which is a key part of

Latest news

  • 2018 by Darwin 2018 by Darwin

    This is not a new trend. Abbott to Abbott/AbbVie is high profile example but so is spinning off specialised businesses such as Novartis Oncology.

  • Novartis’ Promacta receives US breakthrough therapy designation Novartis’ Promacta receives US breakthrough therapy designation

    Novartis’ Promacta receives US breakthrough therapy designation. Regulatory filings of the rare blood disorder treatment are expected this year. ... Samit Hirawat, head of Novartis oncology global drug development, said: “Promacta is a promising

  • Novartis' orphan drug Tasigna wins EU expanded indication Novartis' orphan drug Tasigna wins EU expanded indication

    Novartis' orphan drug Tasigna wins EU expanded indication. The CML medication can now treat paediatric patients. ... Bruno Strigini, chief executive officer, Novartis Oncology, said: “Treatment options for children with CML have historically been

  • Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data

    Novartis, which is planning to unveil the data at the San Antonio Breast Cancer Symposium (SABCS) in December. ... head of global drug development at Novartis’oncology unit.

  • Roche gets FDA OKs for Alecensa and Zelboraf Roche gets FDA OKs for Alecensa and Zelboraf

    Roche’s oncology business unit chalked up two FDA approvals this week for its new ALK inhibitor Alecensa in first-line lung cancer and BRAF inhibitor Zelboraf in a rare blood ... are no longer broken out of the ‘other oncology’category in

More from news
Approximately 3 fully matching, plus 100 partially matching documents found.

Latest Intelligence

  • Charting a course for expansion Charting a course for expansion

    Charting a course for expansion. David Meek on Ipsen's strategic pillars and hopes in oncology. ... Doing so was the latest move in a 25-year pharma career that has also encompassed stints at Johnson &Johnson, Novartis - including a spell as its oncology

  • Choosing destiny Choosing destiny

    For instance, if Novo Nordisk designs a secular grail model by combining IBM's Watson with its own therapies, it will be different from, for example, Novartis' secular grail model combining ... immuno-oncology and companion diagnostics.

  • Deal Watch June 2016 Deal Watch June 2016

    Protein engineering - towards enhanced biologics. Also active in immuno-oncology, Novartis signed a broad collaboration and licence agreement with Xencor worth a potential $2.56bn covering two bispecific, tumour targeting antibodies, ... Tiered low

  • Deal Watch May 2016 Deal Watch May 2016

    Not under pressure as are GSK and Pfizer, Novartis announced the separation of its pharmaceuticals division into two business units: Novartis Oncology and Novartis Pharmaceuticals. ... The pharmaceuticals company will include Novartis' other interests in

  • Pharma deals in June 2015 Pharma deals in June 2015

    This was the case following the $20bn asset swap deal announced in April 2014 in which Novartis and GSK swapped vaccine and oncology assets. ... Licence, collaboration. 364. Spinifex Pharmaceuticals/ Novartis. Lead candidate EMA401 - oral treatment for

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Pfizer’s Elizabeth Barrett joins Novartis as its oncology head Pfizer’s Elizabeth Barrett joins Novartis as its oncology head

    Pfizer’ s Elizabeth Barrett joins Novartis as its oncology head. She succeeds Bruno Strigini who retires. ... Novartis has appointed Elizabeth Barrett to head up its oncology franchise based at the group’s headquarters in Switzerland.

  • Novartis Oncology head Bruno Strigini to retire Novartis Oncology head Bruno Strigini to retire

    Novartis Oncology head Bruno Strigini to retire. Will leave the Swiss pharma firm, and the industry, next year. ... The head of Novartis Oncology Bruno Strigini is set to step down and retire from the pharmaceutical industry.

  • Rainer Boehm and Hervé Hoppenot join Cellectics board Rainer Boehm and Hervé Hoppenot join Cellectics board

    He said: “Despite many advances in oncology, there remains a need to continue to advance the science to meet the needs of its patients. ... Prior to joining Incyte, Hoppenot was the president of Novartis Oncology and has several senior roles with with

  • Alacrita appoints Anna Casse as MD Alacrita appoints Anna Casse as MD

    Prior to BioVault, Casse held several commercial leadership roles including head of Novartis’ophthalmic global business development and licensing, general manager of Novartis’oncology department and she also spent time at

  • Kymab appoints its first chief medical officer Kymab appoints its first chief medical officer

    Kymab appoints its first chief medical officer. Dr Sonia Quaratino joins the firm from Novartis. ... She previous served Novartis as its global clinical programme leader, transitional clinical oncology, with responsibility for the clinical development of

More from appointments
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest from PMHub

  • Igeahub

    Created and curated by Luca Dezzani, MD, Global Medical Director at Novartis Oncology, the Igea blog provides an industry insider’ s view on important topics related to life sciences and healthcare.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics